

Anti-CD9 [P1/33/2] Bulk Size, 1 mg, Ab01340-10.3-BT View online

## Anti-CD9 [P1/33/2] Bulk Size Ab01340-10.3-BT

This antibody was created using our proprietary Fc Silent<sup>™</sup> engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors. Developed in partnership with Ximbio (www.ximbio.com).

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Human IgG1, Fc Silent<sup>™</sup>, Kappa

Clone Number: P1/33/2

Alternative Name(s) of Target: CD9 antigen; 5H9 antigen; Cell growth-inhibiting gene 2 protein; Leukocyte antigen MIC3; Motility-related protein; MRP-1; Tetraspanin-29; Tspan-29; p24; BTCC-1; DRAP-27

**UniProt Accession Number of Target Protein:** P21926

Published Application(s): FC, IHC

Published Species Reactivity: Human

**Immunogen:** This antibody was raised by immunising mice with acute lymphoblastic leukaemia cells. **Specificity:** This antibody recognises CD9 which is a glycoprotein with four transmembrane domains that is expressed on the surface of various blood cells, such as B lymphocytes, platelets, monocytes and others, and also on neurons and glia on the periphery. It is implicated in different functions, for example cell-cell adhesion, signal transduction and platelet activation.

**Application Notes:** Antibodies against CD9 might be used in characterisation of acute leukaemias, other tumours and for functional studies on platelets. For instance, one group used P1/33/2 during immunohistochemical characterisation of frozen sections of melanoma ABCG2+IGR37 cells xenografts (Taghizadeh et al., 2010). Another group used this antibody (along with other anti-CD9 antibodies) to analyse CD9 expression level and distribution in different breast cancer cells (MDA, MA-11, and MCF-7) and they showed that CD9 might be a useful marcer of the neoplastic cells as its expression was higher in cancer cells than in normal breast cells as well as it was additionally present in the nuclei of the malignant tissue (Rappa et al., 2014).

**Antibody First Published in:** Schlossman et al. CD9 cluster workshop report: cell surface binding and functional analysis. Leucocyte Typing V, Vol 2, Oxford University Press, Oxford, New York and Tokyo, p 1249-51 PMID:

Note on publication: This report describes the characterisation of P1/33/2 antibody.

## **Product Form**

Size: 1 mg Purified antibody in bulk size. Purification: Protein A affinity purified Supplied In: PBS only.

**Storage Recommendation:** Store at 4°C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.